Evosep webinar
Advancing IMMUNOPEPTIDOMICS with Sensitivity, Robustness and High-Throughput
Thursday, APRIL 24th at 4:00 pm CET (10:00 EST)
Immunopeptidomics bridges proteomics and immunology to decode the diverse repertoire of peptides presented by major histocompatibility complex (MHC) molecules. These MHC-bound peptides, known as immunopeptidomes, play a pivotal role in immune recognition, influencing processes such as immune surveillance, infectious diseases, autoimmunity, and cancer.
As research in this field advances, the demand for higher sensitivity, robustness, and throughput in peptide analysis has never been greater. In this webinar, we explore how Evosep One is transforming immunopeptidomics by enabling faster, more reproducible, and high-throughput workflows, helping researchers unravel immune responses with greater precision.
Speakers
Unlocking low-input immunopeptidomics using MAETi
Talk by Julian Beyrle, PhD student, HI-TRON Mainz, DKFZ German Cancer Research Center
Immunopeptidomics has matured into a key technology for advancing personalized cancer immunotherapies. However, current immunopeptidome preparation methods often still require substantial sample inputs or rely on complex technologies like microfluidics, thereby limiting accessibility and scalability. Mild Acid Elution in a Tip (MAETi) offers a simple, antibody-free approach for low-input MHC-I immunopeptidome profiling from 1 million to as few as 25,000 cells. By capturing acid-eluted MHC-I ligands directly on Evotips, complemented by HLA-tailored DDA- and DIA-PASEF in timsTOF mass spectrometers, MAETi achieves unprecedented sensitivity and robustness.
Rapid and Sensitive Immunogenicity Risk Analysis of Early Biotherapeutic Drug Candidates
Talk by Bob Seward, Principal Scientist, Pfizer
Immunogenicity generated against biotherapeutic drugs can lead to both reduced efficacy and safety in patients. Presentation of drug-derived peptides on HLA class II molecules is a risk factor for development of anti-drug antibody responses in patients. Identification of these peptides early in the drug development process is critical for effective de-immunization strategies. We present here a streamlined and sensitive in vitro cellular and LC-MS based assay workflow which improves sample throughput and reduces turnaround times to enable rapid early drug lead immunogenicity risk analysis.
